COMP <GO>
MDGL vs JNJ // EV/EBITDA & P/E VALUATION
Madrigal Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MDGL 2
— JNJ 9
■ METRIC PARITY
LAST: $430.36 (-0.31%) • MKT CAP: $9.97B
valuation
—
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDGL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDGL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.70% | 25.50% | -55.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.91% | 2.97% | -4.88 | JNJ | /fcf-yield <GO> |
| Operating Margin | -31.30% | 34.70% | -66.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -30.10% | 28.50% | -58.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.65 | 5.59 | +2.06 | MDGL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.5 | 60.4 | -30.85 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 23.0x | +1.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $662.49B | -$652.52B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDGL REV | JNJ REV | MDGL GROSS % | JNJ GROSS % | MDGL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $958.4M | $94.19B | 44.0% | 67.9% | -$190.0M | $19.70B |
| FY 2024 | $180.1M | $88.82B | 96.5% | 69.1% | -$457.0M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$324.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDGL // BETA 1.08
JNJ // BETA 1.08